Comparison of ultrasensitive and mass spectrometry quantification of blood-based amyloid biomarkers for Alzheimer’s disease diagnosis in a memory clinic cohort
Abstract Background Alzheimer’s disease (AD) is a complex neurodegenerative disorder with β-amyloid pathology as a key underlying process. The relevance of cerebrospinal fluid (CSF) and brain imaging biomarkers is validated in clinical practice for early diagnosis. Yet, their cost and perceived inva...
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2023-02-01
|
| Series: | Alzheimer’s Research & Therapy |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s13195-023-01188-8 |
| _version_ | 1797865325354549248 |
|---|---|
| author | Christophe Hirtz Germain U. Busto Karim Bennys Jana Kindermans Sophie Navucet Laurent Tiers Simone Lista Jérôme Vialaret Laure-Anne Gutierrez Yves Dauvilliers Claudine Berr Sylvain Lehmann Audrey Gabelle |
| author_facet | Christophe Hirtz Germain U. Busto Karim Bennys Jana Kindermans Sophie Navucet Laurent Tiers Simone Lista Jérôme Vialaret Laure-Anne Gutierrez Yves Dauvilliers Claudine Berr Sylvain Lehmann Audrey Gabelle |
| author_sort | Christophe Hirtz |
| collection | DOAJ |
| description | Abstract Background Alzheimer’s disease (AD) is a complex neurodegenerative disorder with β-amyloid pathology as a key underlying process. The relevance of cerebrospinal fluid (CSF) and brain imaging biomarkers is validated in clinical practice for early diagnosis. Yet, their cost and perceived invasiveness are a limitation for large-scale implementation. Based on positive amyloid profiles, blood-based biomarkers should allow to detect people at risk for AD and to monitor patients under therapeutics strategies. Thanks to the recent development of innovative proteomic tools, the sensibility and specificity of blood biomarkers have been considerably improved. However, their diagnosis and prognosis relevance for daily clinical practice is still incomplete. Methods The Plasmaboost study included 184 participants from the Montpellier’s hospital NeuroCognition Biobank with AD (n = 73), mild cognitive impairments (MCI) (n = 32), subjective cognitive impairments (SCI) (n = 12), other neurodegenerative diseases (NDD) (n = 31), and other neurological disorders (OND) (n = 36). Dosage of β-amyloid biomarkers was performed on plasma samples using immunoprecipitation-mass spectrometry (IPMS) developed by Shimadzu (IPMS-Shim Aβ42, Aβ40, APP669–711) and Simoa Human Neurology 3-PLEX A assay (Aβ42, Aβ40, t-tau). Links between those biomarkers and demographical and clinical data and CSF AD biomarkers were investigated. Performances of the two technologies to discriminate clinically or biologically based (using the AT(N) framework) diagnosis of AD were compared using receiver operating characteristic (ROC) analyses. Results The amyloid IPMS-Shim composite biomarker (combining APP669–711/Aβ42 and Aβ40/Aβ42 ratios) discriminated AD from SCI (AUC: 0.91), OND (0.89), and NDD (0.81). The IPMS-Shim Aβ42/40 ratio also discriminated AD from MCI (0.78). IPMS-Shim biomarkers have similar relevance to discriminate between amyloid-positive and amyloid-negative individuals (0.73 and 0.76 respectively) and A−T−N−/A+T+N+ profiles (0.83 and 0.85). Performances of the Simoa 3-PLEX Aβ42/40 ratio were more modest. Pilot longitudinal analysis on the progression of plasma biomarkers indicates that IPMS-Shim can detect the decrease in plasma Aβ42 that is specific to AD patients. Conclusions Our study confirms the potential usefulness of amyloid plasma biomarkers, especially the IPMS-Shim technology, as a screening tool for early AD patients. |
| first_indexed | 2024-04-09T23:07:29Z |
| format | Article |
| id | doaj.art-6fc3f7aac5d146e7b75806a0e6a82b48 |
| institution | Directory Open Access Journal |
| issn | 1758-9193 |
| language | English |
| last_indexed | 2024-04-09T23:07:29Z |
| publishDate | 2023-02-01 |
| publisher | BMC |
| record_format | Article |
| series | Alzheimer’s Research & Therapy |
| spelling | doaj.art-6fc3f7aac5d146e7b75806a0e6a82b482023-03-22T10:37:30ZengBMCAlzheimer’s Research & Therapy1758-91932023-02-0115111210.1186/s13195-023-01188-8Comparison of ultrasensitive and mass spectrometry quantification of blood-based amyloid biomarkers for Alzheimer’s disease diagnosis in a memory clinic cohortChristophe Hirtz0Germain U. Busto1Karim Bennys2Jana Kindermans3Sophie Navucet4Laurent Tiers5Simone Lista6Jérôme Vialaret7Laure-Anne Gutierrez8Yves Dauvilliers9Claudine Berr10Sylvain Lehmann11Audrey Gabelle12University of Montpellier, IRMB-PPC, INM, CHU Montpellier, INSERM CNRSResource and Research Memory Center (CMRR), Department of Neurology, Montpellier University HospitalResource and Research Memory Center (CMRR), Department of Neurology, Montpellier University HospitalUniversity of Montpellier, IRMB-PPC, INM, CHU Montpellier, INSERM CNRSResource and Research Memory Center (CMRR), Department of Neurology, Montpellier University HospitalUniversity of Montpellier, IRMB-PPC, INM, CHU Montpellier, INSERM CNRSResource and Research Memory Center (CMRR), Department of Neurology, Montpellier University HospitalUniversity of Montpellier, IRMB-PPC, INM, CHU Montpellier, INSERM CNRSInstitute for Neurosciences of Montpellier (INM), Univ Montpellier, INSERMInstitute for Neurosciences of Montpellier (INM), Univ Montpellier, INSERMInstitute for Neurosciences of Montpellier (INM), Univ Montpellier, INSERMUniversity of Montpellier, IRMB-PPC, INM, CHU Montpellier, INSERM CNRSResource and Research Memory Center (CMRR), Department of Neurology, Montpellier University HospitalAbstract Background Alzheimer’s disease (AD) is a complex neurodegenerative disorder with β-amyloid pathology as a key underlying process. The relevance of cerebrospinal fluid (CSF) and brain imaging biomarkers is validated in clinical practice for early diagnosis. Yet, their cost and perceived invasiveness are a limitation for large-scale implementation. Based on positive amyloid profiles, blood-based biomarkers should allow to detect people at risk for AD and to monitor patients under therapeutics strategies. Thanks to the recent development of innovative proteomic tools, the sensibility and specificity of blood biomarkers have been considerably improved. However, their diagnosis and prognosis relevance for daily clinical practice is still incomplete. Methods The Plasmaboost study included 184 participants from the Montpellier’s hospital NeuroCognition Biobank with AD (n = 73), mild cognitive impairments (MCI) (n = 32), subjective cognitive impairments (SCI) (n = 12), other neurodegenerative diseases (NDD) (n = 31), and other neurological disorders (OND) (n = 36). Dosage of β-amyloid biomarkers was performed on plasma samples using immunoprecipitation-mass spectrometry (IPMS) developed by Shimadzu (IPMS-Shim Aβ42, Aβ40, APP669–711) and Simoa Human Neurology 3-PLEX A assay (Aβ42, Aβ40, t-tau). Links between those biomarkers and demographical and clinical data and CSF AD biomarkers were investigated. Performances of the two technologies to discriminate clinically or biologically based (using the AT(N) framework) diagnosis of AD were compared using receiver operating characteristic (ROC) analyses. Results The amyloid IPMS-Shim composite biomarker (combining APP669–711/Aβ42 and Aβ40/Aβ42 ratios) discriminated AD from SCI (AUC: 0.91), OND (0.89), and NDD (0.81). The IPMS-Shim Aβ42/40 ratio also discriminated AD from MCI (0.78). IPMS-Shim biomarkers have similar relevance to discriminate between amyloid-positive and amyloid-negative individuals (0.73 and 0.76 respectively) and A−T−N−/A+T+N+ profiles (0.83 and 0.85). Performances of the Simoa 3-PLEX Aβ42/40 ratio were more modest. Pilot longitudinal analysis on the progression of plasma biomarkers indicates that IPMS-Shim can detect the decrease in plasma Aβ42 that is specific to AD patients. Conclusions Our study confirms the potential usefulness of amyloid plasma biomarkers, especially the IPMS-Shim technology, as a screening tool for early AD patients.https://doi.org/10.1186/s13195-023-01188-8Alzheimer’s diseasePlasmaBiomarkersIPMSSimoaDiagnosis |
| spellingShingle | Christophe Hirtz Germain U. Busto Karim Bennys Jana Kindermans Sophie Navucet Laurent Tiers Simone Lista Jérôme Vialaret Laure-Anne Gutierrez Yves Dauvilliers Claudine Berr Sylvain Lehmann Audrey Gabelle Comparison of ultrasensitive and mass spectrometry quantification of blood-based amyloid biomarkers for Alzheimer’s disease diagnosis in a memory clinic cohort Alzheimer’s Research & Therapy Alzheimer’s disease Plasma Biomarkers IPMS Simoa Diagnosis |
| title | Comparison of ultrasensitive and mass spectrometry quantification of blood-based amyloid biomarkers for Alzheimer’s disease diagnosis in a memory clinic cohort |
| title_full | Comparison of ultrasensitive and mass spectrometry quantification of blood-based amyloid biomarkers for Alzheimer’s disease diagnosis in a memory clinic cohort |
| title_fullStr | Comparison of ultrasensitive and mass spectrometry quantification of blood-based amyloid biomarkers for Alzheimer’s disease diagnosis in a memory clinic cohort |
| title_full_unstemmed | Comparison of ultrasensitive and mass spectrometry quantification of blood-based amyloid biomarkers for Alzheimer’s disease diagnosis in a memory clinic cohort |
| title_short | Comparison of ultrasensitive and mass spectrometry quantification of blood-based amyloid biomarkers for Alzheimer’s disease diagnosis in a memory clinic cohort |
| title_sort | comparison of ultrasensitive and mass spectrometry quantification of blood based amyloid biomarkers for alzheimer s disease diagnosis in a memory clinic cohort |
| topic | Alzheimer’s disease Plasma Biomarkers IPMS Simoa Diagnosis |
| url | https://doi.org/10.1186/s13195-023-01188-8 |
| work_keys_str_mv | AT christophehirtz comparisonofultrasensitiveandmassspectrometryquantificationofbloodbasedamyloidbiomarkersforalzheimersdiseasediagnosisinamemorycliniccohort AT germainubusto comparisonofultrasensitiveandmassspectrometryquantificationofbloodbasedamyloidbiomarkersforalzheimersdiseasediagnosisinamemorycliniccohort AT karimbennys comparisonofultrasensitiveandmassspectrometryquantificationofbloodbasedamyloidbiomarkersforalzheimersdiseasediagnosisinamemorycliniccohort AT janakindermans comparisonofultrasensitiveandmassspectrometryquantificationofbloodbasedamyloidbiomarkersforalzheimersdiseasediagnosisinamemorycliniccohort AT sophienavucet comparisonofultrasensitiveandmassspectrometryquantificationofbloodbasedamyloidbiomarkersforalzheimersdiseasediagnosisinamemorycliniccohort AT laurenttiers comparisonofultrasensitiveandmassspectrometryquantificationofbloodbasedamyloidbiomarkersforalzheimersdiseasediagnosisinamemorycliniccohort AT simonelista comparisonofultrasensitiveandmassspectrometryquantificationofbloodbasedamyloidbiomarkersforalzheimersdiseasediagnosisinamemorycliniccohort AT jeromevialaret comparisonofultrasensitiveandmassspectrometryquantificationofbloodbasedamyloidbiomarkersforalzheimersdiseasediagnosisinamemorycliniccohort AT laureannegutierrez comparisonofultrasensitiveandmassspectrometryquantificationofbloodbasedamyloidbiomarkersforalzheimersdiseasediagnosisinamemorycliniccohort AT yvesdauvilliers comparisonofultrasensitiveandmassspectrometryquantificationofbloodbasedamyloidbiomarkersforalzheimersdiseasediagnosisinamemorycliniccohort AT claudineberr comparisonofultrasensitiveandmassspectrometryquantificationofbloodbasedamyloidbiomarkersforalzheimersdiseasediagnosisinamemorycliniccohort AT sylvainlehmann comparisonofultrasensitiveandmassspectrometryquantificationofbloodbasedamyloidbiomarkersforalzheimersdiseasediagnosisinamemorycliniccohort AT audreygabelle comparisonofultrasensitiveandmassspectrometryquantificationofbloodbasedamyloidbiomarkersforalzheimersdiseasediagnosisinamemorycliniccohort |